As linkers become increasingly sophisticated, more emphasis is being placed on the methods of bioconjugation between linker and antibody, with the goal of producing homogeneous adc populations. The basic principle behind adcs is to link antibodies with cytotoxic drugs through a linker, allowing the drug to be selectively delivered to tumor cells, thus enhancing therapeutic efficacy and reducing toxicity to healthy cells Linker tethering payload to antibody is vital for adc
Official teaser showing the leaked wallpaper | Scrolller
This review provides an overview of linkers of 17 approved adcs and recent innovations in linker design, focusing on drug release triggers, bioconjugation strategies, the impact of spacers on hydrophilicity, traceless drug release, and linker architecture, as well as a discussion of the bystander effect, offering insights for the rational.
Target, antibody, linker, payload, and conjugation method.
An antibody is linked to a small molecule via a covalent tether The chemistries used to link the two crucial components of adcs have evolved over time, leading to improved performance Selection of the optimal linker chemistry is paramount to successful development of adcs, however
